NR1H4 and obesity disorder: Notably, constitutive signalling of intestinal FXR as a result of bile acid agonists produced in liver appears to aggravate obesity, insulin resistance and fatty liver, and thus antagonism of intestinal FXR may be a reasonable therapeutic strategy.